Skip to content

Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02059811
Enrollment
42
Registered
2014-02-11
Start date
2014-02-28
Completion date
2014-08-31
Last updated
2014-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Hypertension

Keywords

Kidney Diseases, Renal Insufficiency, Chronic, Diet, DASH diet, Hypertension, Vascular diseases, Cardiovascular Diseases, Blood pressure

Brief summary

More than two-thirds of US adults with chronic kidney disease (CKD) have uncontrolled hypertension. Both hypertension and CKD are major independent risk factors for cardiovascular disease, which is the leading cause of death in the US. Fortunately, lowering blood pressure to recommended treatment targets not only slows the progression of CKD, but also improves cardiovascular outcomes. Controlling hypertension in this patient population, however, can be quite challenging. A lifestyle modification that effectively reduces blood pressure in both pre-hypertensive and hypertensive adults is the Dietary Approaches to Stop Hypertension (DASH) diet. The purpose of this pilot study is to (1) determine the extent to which the DASH diet lowers blood pressure in hypertensive adults with moderate chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] 30-59 ml/min/1.73m2) and (2) establish that the DASH diet can be safely consumed by this patient population.

Detailed description

During a 7-day run-in phase, participants will first consume a control diet similar in nutrient composition to the control diet of previous DASH studies. The control diet, which is a diet typical of most Americans, is reduced in servings of fruits, vegetables, low fat dairy products and relatively high in total and saturated fat. Immediately following the run-in phase, participants will receive the DASH diet during a 14-day intervention phase. Both diets will have the same sodium content and caloric intake will be adjusted for each participant to keep weight stable. All study meals and snacks will be provided.

Interventions

OTHERDASH Diet

The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.

OTHERControl Diet

The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years old * eGFR 30-59 ml/min/1.73m2 * SBP ≥ 130 mmHg or DBP ≥ 80 mmHg * willing to eat one meal on-site 5 days/week

Exclusion criteria

* baseline potassium \>4.6 mEq/L while not taking potassium supplements (if potassium is ≥ 5.0 while taking potassium supplements, a potassium of 4.6 or less must be demonstrated off supplements * evidence of hyperkalemia (\>5.1 mEq/L) within last 6 months * ≥ 0.5 mg/dl increase in serum creatinine in past 6 months * albumin-to-creatinine ratio \> 200 mg/mmol * insulin requiring or poorly controlled diabetes mellitus * cardiovascular event within previous 6 months * change in anti-hypertensive medications in last 2 weeks, or anticipated medication change during study period * unwillingness to eat only study food for 21 day study period * unwillingness or inability to discontinue vitamin and mineral supplements or antacids containing potassium, magnesium or calcium * use of aldosterone antagonist * use of oral corticosteroids * alcohol intake \>14 drinks/week * unstable doses of psychotropics or phenothiazine * weight reducing medications * use of medications for erectile dysfunction during study period * pregnant, breast feeding, or planning pregnancy during study period * chronic disease that may interfere with participation * history of organ transplant * any serious illness that would interfere with participation or make DASH diet unsafe * planning to leave the area during the study period * significant food allergies, preferences, or dietary requirements that would interfere with diet adherence * investigator discretion for safety or compliance reasons

Design outcomes

Primary

MeasureTime frameDescription
Change in office systolic blood pressure2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention systolic blood pressure will be completed.

Secondary

MeasureTime frameDescription
Change in serum potassium2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention serum potassium will be completed.

Other

MeasureTime frameDescription
Change in markers of mineral metabolism2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention markers of mineral metabolism (calcium, phosphorus, intact parathyroid hormone, and 25-hydroxyvitamin D) will be completed.
Change in serum electrolytes2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention electrolytes (bicarbonate, urea nitrogen) will be completed.
Change in blood pressure2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention office diastolic blood pressure and 24 hour ambulatory systolic and diastolic blood pressure will be completed.
Change in 24 hour urinary excretion2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention urinary excretion of sodium, potassium, urea nitrogen, calcium, phosphorus, magnesium, creatinine, and albumin will be completed.
Change in fasting glucose2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention fasting glucose will be completed.
Change in markers of kidney function2 weeks post DASH diet interventionA comparison of pre-intervention and post-intervention markers of kidney function (creatinine, eGFR, and urine albumin-to-creatinine ratio) will be completed.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026